The Food and Drug Administration on Friday approved Novartis AG's Afinitor for use in combination with another drug to treat a common type of breast cancer. Afinitor was initially approved to treat kidney cancer in 2009. Analysts have said the wider approval for use in breast cancer is likely to push...
FULL ARTICLE AT Asian Wall Street Journal